-
Mashup Score: 0Steroid-Refractory cGvHD: Emerging Treatment Options - 6 day(s) ago
This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Diagnosis and Initial Management of cGVHD - 7 day(s) ago
This segment focuses on the key considerations for diagnosing cGvHD and the initial treatment approaches, including the use of corticosteroids and combination therapies. The discussion covers factors that guide the decision-making process, such as organ involvement, severity of symptoms, and response to initial therapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
This segment covers key considerations for diagnosing and treating #cGvHD, including corticosteroids, combination therapies, and factors like organ involvement and symptom severity. @MGHCancerCenter @CatherineLeeMD @huntsmancancer @UCLAHealth https://t.co/CAuWhJ1gxt
-
-
Mashup Score: 3Use of Subsequent Therapies in SR/D cGvHD - 3 month(s) ago
Experts discuss the treatments for steroid-refractory/dependent chronic Graft vs Host Disease (SR/D cGvHD), focusing on the unique mechanisms and applications of belumosudil and role of ibrutinib.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
In a discussion for #cGvHD treatment, experts shed light on belumosudil's and ibrutinib's distinct mechanisms and effectiveness against steroid-resistant forms. @UniFreiburg @dukemedicine https://t.co/rsIEJljl4F
-
-
Mashup Score: 7ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party - 3 month(s) ago
Bone Marrow Transplantation – ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party
Source: www.nature.comCategories: General Medicine News, Hematologists1Tweet-
Ruxo vs ECP for #cGVHD: no winners https://t.co/v8qpS8jBnI
-
-
Mashup Score: 0Various Doses of Axatilimab Generate Positive Responses in cGVHD - 9 month(s) ago
Positive topline results from the AGAVE-201 trial have led the companies to submit a biologics license application to the FDA by the end of 2023.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Axatilimab achieved an overall response rate of 74% at a dose of 0.3 mg/kg given every 2 weeks in adult and pediatric patients with #cGVHD following 2 or more prior lines of therapy. https://t.co/OsgeupxeAx
-
-
Mashup Score: 0Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease - 10 month(s) ago
Key Points. Treatment with abatacept in steroid-refractory cGVHD was associated with a 58% ORR with all responders achieving a PR.Treatment with abatacept was w
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#Phase2 clinical trial evaluating #Abatacept in patients with steroid-refractory chronic #GraftVersusHostDisease 👉https://t.co/Bu3TjvkAqE @BloodJournal @BIDMChealth @JacalynRosenbl2 #cGVHD https://t.co/F2JMMkimL4
-
-
Mashup Score: 0BSA Superior to NIH Skin Scores in Prognosis of Erythema-Type Chronic Graft-Versus-Host Disease - 1 year(s) ago
A new study indicated that body surface area predicted erythema-type chronic graft-vs-host disease survival more accurately than NIH Skin Scores.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Research indicates that body surface area predicted erythema-type chronic graft-vs-host disease survival more accurately than NIH Skin Scores. View the story here: https://t.co/h7hHKRDlJy #cGVHD #dermatology
-
-
Mashup Score: 2Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#FDA Alert: The FDA approved #ibrutinib for #pediatric patients ≥ 1 year of age with chronic graft versus host disease (#cGVHD) after failure of 1 or more lines of systemic #therapy: https://t.co/qsLU7mC7QH #FDAOncology #CancerDrugs #Oncology https://t.co/4sxejgYolW
-
-
Mashup Score: 7
FDA approves ibrutinib for pediatric patients with chronic graft versus host disease, including a new oral suspension
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA approved ibrutinib (Imbruvica, Pharmacyclics) for #pediatric patients ≥ 1 year with chronic graft v host disease (#cGVHD) after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets and oral suspension. #OCENewsBurst https://t.co/gGEx1ZLBSf
-
-
Mashup Score: 0
Researchers sought to determine the effect of chronic graft-versus-host disease on late effects after HCT in pediatric cancer survivors.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A study evaluating late effects of #alloHCT on pediatric survivors of cancer suggests that chronic graft-versus-host disease is associated with nonmalignant effects, but not with subsequent neoplasms. With @ASTCT_Journal. https://t.co/Lq9mWt5zej #cGVHD #PediatricCancer
-
This segment delves into managing steroid-refractory #cGvHD, focusing on data from clinical trials involving agents such as ibrutinib and ruxolitinib. @MGHCancerCenter @CatherineLeeMD @huntsmancancer @UCLAHealth https://t.co/Jl5VSyTW0h